Suz-Anne Kinney
The MarketWatch Blog is Transitioning to ResourceWise Forest Products
Forest2Market: July 14, 2023
In May, the US Department of Agriculture approved requests by Arborgen, a company created by MeadWestvaco, International Paper, and Rubicon, a New Zealand company, to plant 260,000 genetically engineered, sub-tropical Eucalyptus trees throughout the South.
According to the Environmental Assessment conducted by the USDA’s Animal and Plant Health Inspection Service (APHIS), the trees planted will be genetically modified in the following ways:
These plants . . . have been genetically engineered with different constructs. The purpose of the field trials is to test the effectiveness of the CBF gene which is intended to confer cold tolerance and to test the efficacy of the Barnase gene designed to alter fertility. In a small set of experiments, the CBF and Barnase genes are also being tested in combination with genes introduced to alter lignin biosynthesis.
Arborgen began testing these genetically engineered trees in 2008 on 57 acres in the South, though trees on only two of the plots were allowed to flower. Although the exact location of the sites for the upcoming expanded trials are considered confidential business information and not publically available, 28 sites have been approved. All but a holding area in South Carolina will be allowed to flower. In the first round, 5 trials were terminated; Arborgen does not have current plans to continue trials on these sites.
